Long-Term Investment or Short-Term? The Meet Group, Inc. (MEET), Ohr Pharmaceutical, Inc. (OHRP)

The shares of The Meet Group, Inc. (NASDAQ:MEET) and Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) were among the active stocks of the last trading sessions. The Meet Group, Inc. (NASDAQ:MEET) declined to -4.45% closing at the price of $5.15 whereas the shares of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) soared 17.57% with the increase of 0.04 points closing at the price of $0.24. The Meet Group, Inc. has currently increase 123.91% in its stock over the period of 6-months while its rival Ohr Pharmaceutical, Inc. subtracted -2.32% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of The Meet Group, Inc. (NASDAQ:MEET) is -23.1% while the ROI of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) is 0%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, MEET’s EBITDA Margin is 18.36 whereas OHRP’s is -0.6.

Both the profitability ratios suggest a mixed sentiment for The Meet Group, Inc. (NASDAQ:MEET) and Ohr Pharmaceutical, Inc. (NASDAQ:OHRP).

EPS & Surprise Factor

The Meet Group, Inc. (NASDAQ:MEET) reported $0.08/share EPS for the previous quarter where analysts were predicting an EPS to be $0.06/share Thus beating the analyst Estimates with a Surprise Factor of 33.3 Percent. While, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) reported EPS of $-0.05/share in the last quarter. The analysts projected EPS of $-0.07/share depicting a Surprise of 28.6 Percent.

Taking a look at Earnings per Share, The Meet Group, Inc. tends to be beating the analyst estimates more than Ohr Pharmaceutical, Inc.. so MEET is more profitable than OHRP.

Technical Analysis of The Meet Group, Inc. & Ohr Pharmaceutical, Inc.

Moving average convergence divergence (MACD) shows that The Meet Group, Inc. (NASDAQ:MEET) is on a PRICE RELATIVITY trend While Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the The Meet Group, Inc. was in BULLISH territory and Ohr Pharmaceutical, Inc. was in BULLISH territory.

MEET’s current statistics gauge that the stock candle is BEARISH with MEDIUM volatility. While OHRP’s candle is BULLISH with HIGH.

EPS Growth Rate: MEET’s 20% versus OHRP’s 0%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of The Meet Group, Inc. (NASDAQ:MEET) is predicted at 20% while Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) stands at 0%. These numbers suggest that MEET is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of MEET stands at 1.2 while OHRP is at 5.5 whereas the debt ratio of the prior is 0.26 while the debt ratio of the later is 0.01.

The values of the both ratios suggest that one is more liquid and other investment is more risk free.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 1.7 for MEET and 3 for OHRP which means MEET has Buy rating whereas OHRP has Hold rating.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

MEET currently has price to earning P/E ratio of 0 whereas OHRP has 0 while the forward P/E ratio for the prior stands at 14.31 and for the later it depicts the value of 0.

The price to Book P/B for MEET is 2.03, Price to Sale is at 2.51 and for OHRP these ratios stand at 0.8 and 0.